Status:
COMPLETED
Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients
Lead Sponsor:
Centre Hospitalier de Cornouaille
Conditions:
Covid19
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in December 2019 in Wuhan, China. Infection with this new coronavirus called SARS-CoV-2 can lead to fatal ...
Detailed Description
The aim of this study is to evaluate the humoral response after vaccination against SARS-CoV-2 in a French multicenter cohort of patients with hemopathies. Analysis of hemopathies and immunochemothera...
Eligibility Criteria
Inclusion
- Benign or malignant hemopathy
- With priority vaccination indication
- Having benefited from anti-covid-19 mRNA vaccination
Exclusion
- Patients under legal protection
- Palliative care patients
- History of known Covid-19 disease (\<1 year)
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04852796
Start Date
April 1 2021
End Date
April 1 2023
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de Quimper Cornouaille
Quimper, France, 29000